Sci Rep:病灶间的异质性挑战了分子分型在原发性前列腺癌中的临床使用

2019-10-03 AlexYang MedSci原创

前列腺癌是高度异质性的疾病,并且在起始诊断时往往具有典型的多个不同的癌症病灶。前列腺癌的分子分型能够游离的辅助精准的诊断和治疗。在癌症基因组数据库(TCGA)中公开了一个很有前景的分型工具,并基于每个患者的癌症样本成功的对74%的原发性前列腺癌分型,共分成了7组。最近,有研究人员探索了该分型工具的临床使用情况,他们在一个多病灶的背景下对该分型工具进行了测试。研究人员共分析了来自于39名患者的85个

前列腺癌是高度异质性的疾病,并且在起始诊断时往往具有典型的多个不同的癌症病灶。前列腺癌的分子分型能够游离的辅助精准的诊断和治疗。在癌症基因组数据库(TCGA)中公开了一个很有前景的分型工具,并基于每个患者的癌症样本成功的对74%的原发性前列腺癌分型,共分成了7组。

最近,有研究人员探索了该分型工具的临床使用情况,他们在一个多病灶的背景下对该分型工具进行了测试。研究人员共分析了来自于39名患者的85个不同癌症病灶的106个癌症样本。通过来源于全外显子组测序和靶标定性和定量基因表达试验的体细胞变异数据,31%的患者特异性的归类到了7个TCGA组中的1组。更多的是,在12%的病灶中,来自于同一病灶的不同样本具有矛盾的分型。

最后,研究人员指出,病灶内和病灶间的抑制性是密集存在的,并在在开发原发性前列腺癌的分子分型工具中必须给予考虑。

原始出处:

Kristina Totland Carm, Andreas M. Hoff, Anne Cathrine Bakken et al. Interfocal heterogeneity challenges the clinical usefulness of molecular classification of primary prostate cancer. Sci Rep. 19 Sep 2019

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1689932, encodeId=f37e16899326b, content=<a href='/topic/show?id=c5f2226e9d3' target=_blank style='color:#2F92EE;'>#临床使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22679, encryptionId=c5f2226e9d3, topicName=临床使用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=703d28925250, createdName=12498e87m48暂无昵称, createdTime=Sun May 24 05:09:00 CST 2020, time=2020-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1846818, encodeId=979b1846818ac, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Tue Jul 28 13:09:00 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040560, encodeId=5cbe104056091, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Oct 03 17:09:00 CST 2019, time=2019-10-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1689932, encodeId=f37e16899326b, content=<a href='/topic/show?id=c5f2226e9d3' target=_blank style='color:#2F92EE;'>#临床使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22679, encryptionId=c5f2226e9d3, topicName=临床使用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=703d28925250, createdName=12498e87m48暂无昵称, createdTime=Sun May 24 05:09:00 CST 2020, time=2020-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1846818, encodeId=979b1846818ac, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Tue Jul 28 13:09:00 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040560, encodeId=5cbe104056091, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Oct 03 17:09:00 CST 2019, time=2019-10-03, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1689932, encodeId=f37e16899326b, content=<a href='/topic/show?id=c5f2226e9d3' target=_blank style='color:#2F92EE;'>#临床使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22679, encryptionId=c5f2226e9d3, topicName=临床使用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=703d28925250, createdName=12498e87m48暂无昵称, createdTime=Sun May 24 05:09:00 CST 2020, time=2020-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1846818, encodeId=979b1846818ac, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Tue Jul 28 13:09:00 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040560, encodeId=5cbe104056091, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Oct 03 17:09:00 CST 2019, time=2019-10-03, status=1, ipAttribution=)]
    2019-10-03 misszhang

    前列腺癌相关研究,学习了,谢谢梅斯

    0